Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).

Fiche publication

Date publication

juillet 2026

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi , Pr MANFREDI Sylvain , Mme HENRIQUES Julie

Tous les auteurs :
Noé C, Henriques J, Chanez B, Vernerey D, Lecomte T, Durand A, Assenat E, Edeline J, Heurgué A, Tougeron D, Manfredi S, Hautefeuille V, Neuzillet C, Roth G, Lagasse JP, Tournigand C, Delaye M, Hollebecque A, Turpin A, Parent P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42520930

Résumé

Biliary tract cancers (BTCs) are rare, heterogeneous tumors associated with a poor prognosis, even after curative-intent surgery. Adjuvant capecitabine is currently the standard of care; however, real-world data on its efficacy and tolerance are lacking.